natgillin/translations-raw huggingface dataset:
A tablet having a first layer that consists of: 
Tableta koja ima prvi sloj koji se sastoji od:
The method according to claim 1, wherein A represents linear or branched (C1-C6)alkyl or halogen. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da A predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu ili atom halogena.
the donor sequence comprises a transgene under the control of an endogenous or exogenous promoter. 
donorska sekvenca sadrži transgen pod kontrolom endogenog ili egzogenog promotora.
A machine in accordance with claim 1, characterized in that said piston (16) comprises lateral guide projections for its rectilinear movement. 
Uređaj prema zahtjevu 1, naznačen time što klip (16) obuhvaća bočne projekcije vodilice za svoje pravocrtno kretanje.
The pharmaceutical composition for oral administration according to any one of claims 1 to 16, wherein the modified release portion further contains an additive which allows water to penetrate into the formulation. 
Tableta za oralnu primjenu prema bilo kojem od zahtjeva 1 do 14, gdje dio s prilagođenim oslobađanjem dalje sadrži aditiv koji omogućuje penetraciju vode u oblik.
The cells or article of manufacture for use according to claims 5 or 7, wherein culturing of said cells in said 3D culture is effected under perfusion. 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s patentnim zahtjevima 5 ili 7, naznačeni time što se uzgoj navedenih stanica u navedenoj 3D kulturi provodi uz perfuziju.
R6, taken together with the carbon atom bearing it, represents —C(O)—; 
, zajedno s ugljikovim atomom koji ga nosi, predstavlja -C(O)-;
In the compounds shown in Scheme 8, R2 is as defined above for Schemes 1 and 2; P3 is a hydroxyl protecting group such as a carbobenzyloxy (CBZ) group; R10 is an alkyl group such as a methyl or ethyl group; and R11 and R12 are defined as for R8 and R9, respectively, for Scheme 6 above. 
U spojevima koji su prikazani u shemi 8, R> je kao što je gore definirano za sheme 1 1 2; Ps je hidroksil zaštitna skupina, kao npr. karbobenziloksi (CBZ) skupina; Ry je alkil skupina, kao npr. metil ili etil skupina; i Rij i Ri, su definirani kao za Rg odnosno Ry za shemu 6 gore.
and R4 together with the nitrogen group form an aliphatic amine. 
R2 1 Rs uzeti zajedno sa dušikovom grupom formiraju alifatični amin.
The relationship between SDS concentration and average microaggregate size, as measured by classical light scattering, has been empirically assessed, as shown in Figure 1. 
Odnos između koncentracije SDS i prosječne veličine agregata, kako je izmjereno klasičnim raspršenim svjetlom, bila je empirijski procijenjena, kako je prikazano na Slici 1.
means for loading the container into the input end of the vacuum chamber; 
sredstvo (36) za utovar posude (38) u ulazni kraj (30) vakuumske komore (22);
a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and (i) citrate and/or (ii) acetate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 5°C for 3 to 6 months of about less than 5 %; 
(a) tekuća vodena farmaceutska formulacija koja sadržava terapijski djelotvornu količinu Adalimumaba u puferiranoj otopini koja sadržava L-histidin i citrat, navedena formulacija ima pH od 5 do 5,5 i ima sadržaj agregiranih vrsta Adalimumaba, nakon skladištenja pri 5 *C tijekom 3 do 6 mjeseci, manje od 5 %;
Use for cleaning water from suspended particles of oil or oil products, and optionally from metal ions, of an aqueous solution of polysaccharide microgels having a concentration of microgels from 0.1 to 20 g/l, wherein the capability of polysaccharides to become adsorbed on an interphase surface in the form of microgels is used, characterized in that the microgels have a molecular mass of 20,000-200,000 Da and a particle size of 50-600 nm, wherein the pH of the solution is changed so as to cause the formation of agglomerates, consisting of said suspended particles of oil or oil products coated with a thin polysaccharide film. 
PATENTNI ZAHTJEVI Upotreba vodene otopine polisaharidnih mikrogelova za pročišćavanje vode od lebdećih čestica nafte ili naftnih proizvoda, 1 opcionalno od metalnih iona, imajući koncentraciju mikrogelova od 0,1 do 20 g/l, naznačeno time da se koristi sposobnost polisaharida da budu adsorbirani na interfaznoj površini u obliku mikrogelova, naznačeno time da mikrogelovi imaju molekularnu masu od 20.000 do 200.000 Da i veličinu čestice od 50 do 600 nm, naznačeno time da je pH vrijednost otopine izmijenjena tako da izazove formiranje aglomerata, sačinjenih od spomenutih lebdećih čestica nafte ili naftnih poizvoda premazanih tankom polisaharidnom opnom.
The method of claim 7, wherein the additional therapeutic agent is at least one selected from the group consisting of glucocorticoides, cyclosporin, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs), TNF-a antagonists, IL-1 antagonists, IL-6 antagonists, and opioids. 
(i) < dodatno terapeutsko sredstvo je najmanje jedno sredstvo odabrano iz grupe koja se sastoji od inzulina ili njegovih analoga, glukokortikosteroida, ciklosporina, metotreksata, nesteroidnih protuupalnih lijekova (NSAID), antagonista TNF-a, antagonista IL-1, antagonista IL-6 i opioida; i/ili
The method describes a procedure to measure solubility of solid material in PaSSIF (Fasted State Simulated Intestinal Fluid). 
Postupak opisuje proceduru mjerenja topljivosti krutine u stimuliranoj crijevnoj tekućini tijekom izgladnjivanja (FaSSIF - Fasted State Simulated Intestinal Fluid).
A Compound of formula Q wherein 
Spoj formule Q gdje
Use of biopolymers for removing phosphorus from wastewater, wherein the biopolymers are isolated using the following method: 
(54) Naziv izuma: UPORABA BIOPOLIMERA ZA ODSTRANJIVANJE FOSFORA IZ OTPADNIH VODA
The aqueous phase was adjusted to basic pH with NaOH (1M) and the phases were separated. 
Vodene faze se prilagode na bazični pH sa NaOH (1M) i potom se faze razdijele.
The pharmaceutical composition of claim 1, wherein the glycopeptide antibiotic is Vancomycin, Teicoplanin, Telavancin, Dalbavancin or Oritavancin. 
Farmaceutski pripravak prema zahtjevu 10, pri čemu je glikopeptidni antibiotik Vankomicin, Teikoplanin, Telavancin, Dalbavancin ili Oritavancin.
The shooter therefore finds him/herself having to keep the muscles involved contracted in order to prevent lessening the elastic grip. 
Pucač stoga nalazi da on/ona treba držati napetima mišiće koji su u to uključeni da bi se na taj način spriječilo smanjenje elastičnog zahvata.
Gemzar®, a process for making it and methods for using it are described in U.S. Pat. No. 5,464,826 and U.S. Pat. No 4,808,614. 
Gemzar", postupak njegovog dobivanja i postupci njegove upotrebe opisani su u US patentu br. 5,464,826 i US patentu br 4,808,614.
represents a hydrogen atom or a C1-6 alkyl group; and n represents 0 to 3; m represents 0 to 1; o represents 0 to 2. 
R7 predstavlja atom vodika ili C,.g alkilnu skupinu; i n predstavlja 0 do 3; m predstavlja 0 do 1; o predstavlja 0 do 2.
The treatment agent for neuropathic pain according to claim 5, wherein one of R2 and R3 represents a hydrogen atom; and the other of R2 and R3 represents an optionally substituted acylamino group. 
Derivat benzopirana za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da jedan od R2 i R3 predstavlja atom vodika, a drugi od R2 i R3 predstavlja po izboru supstituiranu acilamino skupinu.
D comprises a pyrrolobenzodiazepine (PBD); and n is an integer from 1 to 20; and 
D obuhvaća citotoksično sredstvo; i n je cijeli broj od 1 do 20.
from 0 to 25% of calcium aluminoferrite phase having a composition corresponding to the general formula C6Ax′Fy′, with x′ varying from 0 to 1.5 and y′ varying from 0.5 to 3; and from 20% to 70% of C2S belite phase; 
od 0do 25% kalcij aluminoferit faze sa sastavom koji odgovara općoj formuli CgA,F,, sa x' koji varira od 0 do 1.51 y koji varira od 0.5 do 3; te - < od 20 do 70% belit faze C2$S;
Ulipristal acetate (17a-acetoxy-11B-[4- N, N -dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-dione) or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids. 
HR P20140132 T1 PATENTNI ZAHTJEVI Ulipristal acetat (17a-acetoksi-118-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
A kit comprising a compound of the above (1.) or the above (2.) in dry form or the pharmaceutical composition of any one of the above (3.)-(7.) in dry form; and 
Set koji sadrži spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 u suhoj formi ili farmaceutsku kompoziciju bilo kojeg od patentnih zahtjeva 3-7 u suhoj formi; i farmaceutski prihvatljivo tekuće otapalo.
The soft chewable veterinary composition of claim 5, wherein the binder is polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, a co-polymer of vinyl acetate and vinylpyrrolidone, or a polyethylene glycol, or a combination thereof, more preferably, polyvinylpyrrolidone or a polyethylene glycol, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 5, naznačen time, da vezivo je polivinilpirolidon, križno vezani polivinilpirolidon, kopolimer vinilacetata i vinilpirolidona, ili polietilenglikol, ili njihova kombinacija, još poželjnije, polivinilpirolidon ili polietilenglikol, ili njihova kombinacija.
from 0.05 to 5% by weight, preferably from 0.1 to 2% by weight, of at least one fluidizing agent; 
(d) barem jedno sredstvo za superfluidiziranje je od 0,1 do 2% po masi;
hydrogen, substituted and unsubstituted alkyl, and 
(2) supstituirani i nesupstituirani akil, i
The feed according to embodiment 1 or 2, wherein the fatty acid mixture does not essentially contain trans fatty acids, and preferably contains no trans fatty acids. The feed according to any one of embodiments 1-3, wherein the iodine value of the fatty acid mixture is at most 5, preferably at most 3, and most preferably at most 1. The feed according to any one of embodiments 1-4, wherein the fatty acid mixture contains at least 60% palmitic acid (C16:0) and at most 30% stearic acid (C18:0), preferably at least 80% palmitic acid and at most 20% stearic acid, and most preferably the fatty acid mixture contains at least 95% palmitic acid and at most 5% stearic acid. 
Životinjska hrana prema zahtjevu 1, naznačeno time da je talište mješavine masnih kiselina veće od 60%C; i/ili mješavina masnih kiselina u osnovi ne sadrži trans masne kiseline, te poželjno ne sadrži trans masne kiseline; i/ili da je jodni broj mješavine masnih kiselina najviše 5, poželjno najviše 3, a najpoželjnije najviše 1; i/ili da su masne kiseline mješavine masnih kiselina slobodne masne kiseline. Životinjska hrana prema zahtjevu 1 ili 2, naznačeno time da mješavina masnih kiselina sadrži barem 80% palmitinske kiseline 1 najviše 20% stearične kiseline, poželjno barem 95% palmitinske kiseline i najviše 5% stearične kiseline; i/ili mješavina masnih kiselina sadrži sljedeće masne kiseline u %:
The filter of claim 1, wherein the ratio of the thickness of the unitary closed edge to the thickness of the strands is from 0.5 to 2. 
Filtar prema bilo kojem od zahtjeva 7 do 10, gdje je omjer debljine jedinstvenog zatvorenog ruba i debljine niti od 0.5 do 2.
The method according to claim 1, wherein the catalyst (N-cat) is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilicates, acidic ion exchange resins, carbon treated with HCl, H2SO4 or HNO3, and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 9, naznačen time da katalizator (N-kat.) bude odabran iz skupine koja se sastoji iz octene kiseline, mravlje kiseline, trifluoroctene kiseline, metansulfonske kiseline, ptoluolsulfonske kiseline, HC1, HBr, H2SO4, H3PO4, BCI3, BF30Et2, MgC12, MgBr2, AICI3, ZnC12, Cu(BF4)2, alumino silikata, kiselih smola ionskih izmjenjivača, s ugljikom tretiranim HCI, H2SO4 ili HNO3 i njihovim mješavinama.
A lighting module of claim 1, wherein said microchip is configured to operate the switching device such that 875 mA to 930 mA is delivered to the light emitting diode when said thermistor senses between 20°C to 30°C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 875 mA do 930 mA kada navedeni termistor odčita temperaturu u rasponu 20°C - 30°C.
at least 15 µg compound of formula (1) or (2)/kg/minute. 
(e) najmanje 15 ug spoja sa formulama (1) ili (2)/kg/minuti.
The isolated human antibody of 13, wherein the human heavy chain CDR1 region is the heavy chain CDR1 region of NGF as shown in SEQ ID NO: 22 and the human light chain CDR1 region is the light chain CDR1 region shown in SEQ ID NO: 24. The antibody of 13, wherein the antibody dissociates from a human NGF polypeptide with a KD of about 1x10-9 or less and neutralizes human NGF bioactivity in a standard in vitro assay with an IC50 of about 1 x 10-8 M or less. 
NO: 43. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 7, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44 i teški lanac čiji je slijed SEQ ID NO: 40. Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1-8, naznačen time da se antitijelo ili antigen vezujući fragment odvaja od humanog NGF polipeptida s Kp (konstantno disocijacije) od 4 x 107"M.
The order of isomer elution is the same for both normal and reverse-phase columns. 
Redoslijed eluacije izomera je jednak i kod obrnuto-fazne i kod normalno-fazne kolone.
contacting the pre-incubated sample with HPVLPs, consisting predominantly of the VLP1 protein of the JCV, immobilized on a solid substrate under conditions suitable for binding of a JCV antibody in the sample to an HPVLP; 
(b) stavljanju u kontakt predinkubiranog uzorka s HPVLP-ima, koji se pretežno sastoje od proteina VP1 iz JCV, imobiliziranih na čvrsti supstrat u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP;
A process according claim 25, wherein step (c) comprises treating the salt form of isomer IIIb with an acid to form isomer IIIb. A process according to claim 30 wherein the acid is HCl. 
Postupak u skladu s patentnim zahtjevom 12 ili patentni zahtjev 13, naznačen time što se korak (c) sastoji u obradi solnog oblika izomera IIIb kiselinom kako bi se dobilo izomer IIIb.
Step A: Formula for Drug Adsorption on to the Excipients 
Korak A: Formula za adsorpciju lijeka na ekscipijente
at least a binary input adapted to receive one or more candidate signals; 
najmanje binarni ulaz (2), prilagođen za primanje jednog ili više kandidatnih signala (S.);
The melting point of these chemicals is of an interesting order of magnitude, for example about 60°C, and they also have a suitable boiling point of about 210°C, for example. 
Tališta tih zanimljivih kemikalija dosižu, na primjer, pribl. 60"C, i one također imaju prikladna vrelišta od pribl. 210"C, na primjer.
The compound according to claim 9, wherein the salt is selected from the group consisting of sodium, potassium, magnesium, hemifumarate, hydrochloride and hydrobromide, 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da je sol odabrana iz skupine koja se sastoji od natrija, kalija, magnezija, hemifumarata, hidroklorida i hidrobromida.
A system for remote metering the consumption of utilities distributed through a public distribution network (HV, MV, LV) to a plurality of consumers (H1, H2,..., Hn), the system comprising 
Sustav za daljinsko mjerenje potrošnje komunalnih usluga distribuiranih putem javne distribucijske mreže (HV, MV, LV) za velik broj potrošača (H1, H2,..., Hn), pri čemu se sustav sastoji od
Example 2: Crystallization of batch C1 (monoclinic polymorph) 
Kristalizacija serije CI (monoklinski polimorf)
First, there is a high upper limit on the size of the proteins that can be purified using this technique; second the technique does not require the use of protein-denaturing organic solvents. 
Prvo, postoji gornja granica na veličinu proteina koji se mogu pročistiti ovom tehnikom; a drugo, ova tehnika ne zahtjeva uporabu organskih otapala za denaturaciju proteina.
Finally, the adhesive must ensure a reliable adhesive joint, if, for example, pieces of wood having a high wood humidity (wet) should be glued to each other. 
Na kraju, ljepilo mora osigurati pouzdan spoj dobiven lijepljenjem, ako, na primjer, komadi od drva, koji se trebaju zalijepiti jedan s drugim, imaju visoku vlažnost drva (ako su mokri).
Process for the purification of perindopril A dicyclohexyamine salt of compound of formula I, namely perindopril, having an X-ray powder diffraction pattern with characteristic peaks (2θ): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409, and 14.540. 
Dicikloheksilamin sol spoja formule I, odnosno perindoprila, koja ima uzorak difrakcije X-zraka na prahu sa slijedećim karakterističnim signalima (20): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409 i
This effect is particularly pronounced with hydroxyalkyl chitosans and carboxyalkyl chitosans. 
Ovaj učinak naročito je izražen uz hidroksialkilne hitosane i karboksialkilne hitosane.
wherein the glazed panel is configured such that it can run vertically up and down in the balcony pillars and wherein the glazed panel comprises lamellar glass in a frame and wherein the glazed panel is balanced by a counterweight, wherein the balcony pillars of the balcony fence are vertical and have a height that extends only to an upper edge of the fixed glass sheets between the balcony pillars, 
Balkonska ograda prema zahtjevu 1, naznačena time da okomiti balkonski stupovi (2) balkonske ograde (1) imaju visinu koja se pruža samo u gornjeg ruba fiksne staklene ploče (3) između balkonskih stupova (2), što vrijedi i za stupove koji se nalaze uz zidove i na uglovima.
A pharmaceutical composition comprising: suitable pharmaceutical excipients; and a human in vivo clinical effective amount of a recombinant human growth hormone (rhGH) PEGylated prodrug conjugate, wherein PEG is linked to rhGH via a self hydrolysable (autocleavage) transient linker from which the rhGH is released in its native form; 
PATENTNI ZAHTJEVI 1. Farmaceutski sastav koji obuhvaća prikladna pomoćna sredstva i također sadrži za čovjeka klinički učinkovitu količinu in vivo rekombinantnog ljudskog hormona rasta (rhGH)-PEGilirani predlijek-konjugata, pri čemu je PEG povezan s rhGH preko samohidrolizirajućeg (samocijepajućeg) prijelaznog poveznog elementa; gdje je navedeni predlijek-konjugat naznačen time, da:
blending and/or sieving the product obtained in step (iii); and separately 
(iv) miješanje i/ili prosijavanje produkta dobivenog u koraku (iii); i zasebno
is independently selected from: halogen, phenyl and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NRa, O and S(O)p; wherein said phenyl and heteroaryl are substituted with 0-3 R3A; 
je neovisno odabran od: halogena, fenila i 5-članog do 6-članog heteroarila koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O i S(O)p; pri čemu su navedeni fenil i heteroaril supstituirani s 0-3 R3A;
Glucagon receptor activation promotes protein kinase A-dependent phosphorylation of phosphorylase kinase. 
Aktivacija receptora glukagona promovira fosforilaciju fosforilaza kinaze ovisne o protein kinazi A.
Preferably a small amount of a lower alkanoic acid such as acetic acid is added to neutralise the solution. 
Poželjno se dodaje mala količina neke takve niže alkanove kiseline kao što je octena kiselina da se otopina neutralizira.
A compound of claim 14, wherein R1 is methyl; and m is 0-2. 
Spoj u skladu s patentnim zahtjevom 14, naznačen time, da je R1 metil, a m je 0 do 2.
This presents a challenge for even application to forage 8. 
To stvara izazov za ravnomjerno nanošenje na krupnu stočnu hranu 8.
In some embodiments, carbidopa may act as an agent that inhibits the formation of oxidation products. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 3, nadalje sadržeći agent koji inhibira stvaranje produkata oksidacije.
A sealable container according to embodiment 1, 2 or 3, wherein the adhesive is an adhesive based on a polymeric substrate or a polyethylene(PE) or PE co-polymer based material. 
Posuda prema patentnim zahtjevima 1, 2 ili 3, pri čemu, lepak je lepak na bazi polimernog supstrata ili polietilena (PE) ili materijala na bazi PE kopolimera.
said dsRNA duplex has a length of from 8 base pairs (bp) to 15 bp; 
(i) navedeni dsRNA dupleks ima duljinu od 8 parova baza (bp) do 15 bp;
access for placing items into the container or removing items from the container is provided through an upper portion of the container. 
je ulaz za postavljanje predmeta u spremnik ili uklanjanje predmeta iz spremnika predviđen kroz gornji dio spremnika.
adding the substituted benzimidazol to the solution obtained in step (a) and 
dodavanje pimobendana ili njegove farmaceutski prihvatljive soli u otopinu koja je dobivena u koraku a); i
The method of claim 1, comprising administering an effective amount of at least one further compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplerenone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, bromocriptine or torasemide, or pharmaceutically acceptable salt(s) thereof. 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difiln, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
Formulation of the compositions according to the invention can conveniently be effected by methods known from the art, for example, as described in Remington's Pharmaceutical Sciences, 17th ed., 1995 . 
Formulacije pripravaka prema izumu mogu se konvencionalno izvoditi metodama poznatim u struci, na primjer, kako je opisano u Remington's Pharmaceutical Sciences, 17.izdanje, 1995.
Method for the control of power ramp-rates minimizing energy storage requirements in intermittent power generation plants according to claim 1 characterized in that the maximum plant power, PMax(t), and/or the minimum plant power, PPV,Min(t) are calculated through specific values of meteorological variables, such as wind speed, vw(t), and temperature, T(t), wherein the intermittent power generation plant is a wind turbine or wind farm. 
Metoda za kontrolu brzine napajanja koja minimizira zahtjeve za skladištenjem energije u povremenim postrojenjima za proizvodnju električne energije prema zahtjevu 1, naznačena time što se izračunavaju najveća snaga postrojenja, Pygx(t) i / ili minimalna snaga postrojenja, Pmin(t) putem specifičnih vrijednosti meteoroloških varijabli, poput brzine vjetra, v,(t) i temperatura, T(t), pri čemu je povremena elektrana za proizvodnju energije vjetrenjača ili vjetroolektrana.
BACKGROUND OF THE INVENTION PDE4 inhibitors and antimuscarinic agents, in particular antagonists of M3 muscarinic receptors, are two classes of drugs useful in the treatment of respiratory disorders such as, asthma or Chronic Obstructive Pulmonary Diseases (COPD). 
B-adrenergički agonisti, osobito B2-adrenergički agonisti i antimuskarinski lijekovi, osobito antagonisti M3 muskarinskih receptora, predstavljaju dva razreda bronhodilatacijskih lijekova korisnih u liječenju respiratornih poremećaja, poput astme ili kronične opstruktivne plućne bolesti (KOPD).